The World's Greatest Investing Community
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
Synergy Pharmaceuticals, Inc. (Synergy) is a development-stage biopharmaceutical company. The Company primarily focuses on the development of drugs to treat gastrointestinal (GI) disorders and diseases. Synergy’s lead drug candidates, acquired from Synergy-DE comprise: SP-304, a guanylyl cyclase C (GC-C) receptor agonist, to treat GI disorders, primarily chronic constipation (CC) and constipation-predominant irritable bowel syndrome (IBS-C) and SP-333, a second generation GC-C receptor analog, which is in the pre-clinical development for the treatment of ulcerative colitis (UC).
UC is the most important medical problem that they are designing drugs for, but they are only in the "pre-clinical development" stage, which means they have a long way to go before having a marketable drug. If they are bought out by a big pharma company or are able to lease a discovery, then they could justify a speculative bet, but limited reimbursement for new medications and difficulty with the FDA makes profitable success less likely.